Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Margherita Maffioli

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
The Lancet. Haematology|May 16, 2022
Making a case for disease-modifying agents in myelofibrosisMargherita Maffioli
Hematology. American Society of Hematology. Education Program|December 4, 2016
Update from the latest WHO classification of MPNs: a user's manualFrancesco Passamonti, Margherita Maffioli
Blood|April 14, 2018
The role of JAK2 inhibitors in MPNs 7 years after approvalFrancesco Passamonti, Margherita Maffioli
The New England Journal of Medicine|March 21, 2014
JAK inhibitor in CALR-mutant myelofibrosisFrancesco Passamonti, Domenica Caramazza, Margherita Maffioli
Oncotarget|December 22, 2017
Therapy of polycythemia vera: is it time to change?Francesco Passamonti, Margherita Maffioli, Barbara Mora
Drugs in Context|October 25, 2019
Standard care and investigational drugs in the treatment of myelofibrosisDaniela Barraco, Margherita Maffioli, Francesco Passamonti
Clinical Advances in Hematology & Oncology : H&O|September 27, 2017
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approachesMargherita Maffioli, Barbara Mora, Francesco Passamonti
Annals of Hematology|October 22, 2018
Treating early-stage myelofibrosisFrancesca Palandri, Elena Sabattini, Margherita Maffioli
European Journal of Internal Medicine|May 26, 2018
Chronic myeloproliferative neoplasms in the elderlyMargherita Maffioli, Ester Orlandi, Francesco Passamonti
Current Opinion in Hematology|January 10, 2012
New generation small-molecule inhibitors in myeloproliferative neoplasmsFrancesco Passamonti, Margherita Maffioli, Domenica Caramazza
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
The Lancet. Haematology|May 16, 2022
Making a case for disease-modifying agents in myelofibrosisMargherita Maffioli
Hematology. American Society of Hematology. Education Program|December 4, 2016
Update from the latest WHO classification of MPNs: a user's manualFrancesco Passamonti, Margherita Maffioli
Blood|April 14, 2018
The role of JAK2 inhibitors in MPNs 7 years after approvalFrancesco Passamonti, Margherita Maffioli
The New England Journal of Medicine|March 21, 2014
JAK inhibitor in CALR-mutant myelofibrosisFrancesco Passamonti, Domenica Caramazza, Margherita Maffioli
Oncotarget|December 22, 2017
Therapy of polycythemia vera: is it time to change?Francesco Passamonti, Margherita Maffioli, Barbara Mora
Drugs in Context|October 25, 2019
Standard care and investigational drugs in the treatment of myelofibrosisDaniela Barraco, Margherita Maffioli, Francesco Passamonti
Clinical Advances in Hematology & Oncology : H&O|September 27, 2017
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approachesMargherita Maffioli, Barbara Mora, Francesco Passamonti
Annals of Hematology|October 22, 2018
Treating early-stage myelofibrosisFrancesca Palandri, Elena Sabattini, Margherita Maffioli
European Journal of Internal Medicine|May 26, 2018
Chronic myeloproliferative neoplasms in the elderlyMargherita Maffioli, Ester Orlandi, Francesco Passamonti
Current Opinion in Hematology|January 10, 2012
New generation small-molecule inhibitors in myeloproliferative neoplasmsFrancesco Passamonti, Margherita Maffioli, Domenica Caramazza
Pageof 8